Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients

Prostate cancer (PCa) is the most common cancer in men worldwide. Despite better and more intensive treatment options in earlier disease stages, a large subset of patients still progress to metastatic castration-resistant PCa (mCRPC). Recently, poly-(ADP-ribose)-polymerase (PARP)-inhibitors have bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Giesen, Alexander, Baekelandt, Loïc, Devlies, Wout, Devos, Gaëtan, Dumez, Herlinde, Everaerts, Wouter, Claessens, Frank, Joniau, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551452/
https://www.ncbi.nlm.nih.gov/pubmed/37810962
http://dx.doi.org/10.3389/fonc.2023.1265812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551452/
https://www.ncbi.nlm.nih.gov/pubmed/37810962
http://dx.doi.org/10.3389/fonc.2023.1265812

Ejemplares similares